Severe late toxicity · women with stage I endometrial cancer
Summary of findings: EBRT leads to higher severe late toxicity compared with no EBRT (high certainty).
1 finding from 1 review
RR 2.58 [1.61, 4.11]
3501 participants
High
Acute and late GI toxicity (grade 2+) · People with urological (prostate) and gynaecological (endometrial) cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Diarrhoea (grade 2+) · People with urological (prostate) and gynaecological (endometrial) cancer
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
QoL · People with urological (prostate) and gynaecological (endometrial) cancer
1 finding from 1 review
Mean GI symptom scores · People with urological (prostate) and gynaecological (endometrial) cancer
1 finding from 1 review
Participant preference · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher participant preference ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher withdrawal any reason ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Lack of efficacy withdrawal · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoids changes withdrawal due to lack of efficacy ( compared with other anti‐emetic agent (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher withdrawal due to adverse event ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of nausea ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of vomiting ( compared with other anti‐emetic agent (moderate certainty).
1 finding from 1 review
Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of nausea and vomiting ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Intervention not reported
MSP compared with IHC · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
Other techniques (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
PSQ compared with IHC · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
PSQ compared with MSP · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
Variants of PSQ · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
qMSP (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
Bead array (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review
Intervention not reported
PCR‐mRNA (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)
1 finding from 1 review